Superfluous, controversial and luxury issues in nuclear medicine

doi:10.1007/s00259-023-06228-x

Editorial

. 2023 Jul;50(9):2582-2587.

doi: 10.1007/s00259-023-06228-x.

Superfluous, controversial and luxury issues in nuclear medicine

Ozgul Ekmekcioglu¹, Samantha Y A Terry², Silvia Morbelli³, Juliano J Cerci⁴, Helle D Zacho⁵, Steffie Peters⁶, Xavier Boulvard Chollet⁷, Fred Verzijlbergen⁸

Affiliations

¹ Department of Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.
² School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
³ IRCCS Ospedale San Martino, Genoa, Italy.
⁴ Quanta - Diagnóstico e Terapia, Curitiba, Brazil.
⁵ Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
⁶ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands.
⁷ Department of Nuclear Medicine, Centro Investigación Biomédica de La Rioja (CIBIR), La Rioja, Logroño, Spain.
⁸ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands. fred.verzijlbergen@gmail.com.

PMID: 37093314
DOI: 10.1007/s00259-023-06228-x

Editorial

Superfluous, controversial and luxury issues in nuclear medicine

Ozgul Ekmekcioglu et al. Eur J Nucl Med Mol Imaging. 2023 Jul.

. 2023 Jul;50(9):2582-2587.

doi: 10.1007/s00259-023-06228-x.

Authors

Ozgul Ekmekcioglu¹, Samantha Y A Terry², Silvia Morbelli³, Juliano J Cerci⁴, Helle D Zacho⁵, Steffie Peters⁶, Xavier Boulvard Chollet⁷, Fred Verzijlbergen⁸

Affiliations

¹ Department of Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.
² School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
³ IRCCS Ospedale San Martino, Genoa, Italy.
⁴ Quanta - Diagnóstico e Terapia, Curitiba, Brazil.
⁵ Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
⁶ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands.
⁷ Department of Nuclear Medicine, Centro Investigación Biomédica de La Rioja (CIBIR), La Rioja, Logroño, Spain.
⁸ Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands. fred.verzijlbergen@gmail.com.

PMID: 37093314
DOI: 10.1007/s00259-023-06228-x

No abstract available

PubMed Disclaimer

References

1. Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S; EANM Neuroimaging Committee. The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033–3036. https://doi.org/10.1007/s00259-021-05485-y .
1. Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, Aarsland D, Agosta F, Babiloni C, Boada M, Borroni B, Cappa S, Dubois B, Frederiksen KS, Froelich L, Garibotto V, Georges J, Haliassos A, Hansson O, Jessen F, Kamondi A, Kessels RPC, Morbelli S, O’Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Ritchie CW, Scheltens P, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Van Der Flier WM, Nobili F, Frisoni GB. European consensus for the diagnosis of MCI and mild dementia: preparatory phase. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12798 . - DOI - PubMed
1. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704. https://doi.org/10.1056/NEJMoa2100708 . - DOI - PubMed
1. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 . - DOI - PubMed - PMC
1. Hofman MS, Emmett L, Sandhu S, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. https://doi.org/10.1016/S0140-6736(21)00237-3 . - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer

[1] Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S; EANM Neuroimaging Committee. The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033–3036. https://doi.org/10.1007/s00259-021-05485-y .

[2] Garibotto V, Albert NL, Barthel H, van Berckel B, Boellaard R, Brendel M, Cecchin D, Ekmekcioglu O, van de Giessen E, Guedj E, Lammerstma AA, Semah F, Traub-Weidinger T, Van Weehaeghe D, Morbelli S; EANM Neuroimaging Committee. The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. Eur J Nucl Med Mol Imaging. 2021;48(10):3033–3036. https://doi.org/10.1007/s00259-021-05485-y .

[3] Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, Aarsland D, Agosta F, Babiloni C, Boada M, Borroni B, Cappa S, Dubois B, Frederiksen KS, Froelich L, Garibotto V, Georges J, Haliassos A, Hansson O, Jessen F, Kamondi A, Kessels RPC, Morbelli S, O’Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Ritchie CW, Scheltens P, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Van Der Flier WM, Nobili F, Frisoni GB. European consensus for the diagnosis of MCI and mild dementia: preparatory phase. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12798 . - DOI - PubMed

[4] Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, Aarsland D, Agosta F, Babiloni C, Boada M, Borroni B, Cappa S, Dubois B, Frederiksen KS, Froelich L, Garibotto V, Georges J, Haliassos A, Hansson O, Jessen F, Kamondi A, Kessels RPC, Morbelli S, O’Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Ritchie CW, Scheltens P, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Van Der Flier WM, Nobili F, Frisoni GB. European consensus for the diagnosis of MCI and mild dementia: preparatory phase. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12798 . - DOI - PubMed

[5] Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704. https://doi.org/10.1056/NEJMoa2100708 . - DOI - PubMed

[6] Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704. https://doi.org/10.1056/NEJMoa2100708 . - DOI - PubMed

[7] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 . - DOI - PubMed - PMC

[8] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 . - DOI - PubMed - PMC

[9] Hofman MS, Emmett L, Sandhu S, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. https://doi.org/10.1016/S0140-6736(21)00237-3 . - DOI - PubMed

[10] Hofman MS, Emmett L, Sandhu S, et al. [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804. https://doi.org/10.1016/S0140-6736(21)00237-3 . - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Superfluous, controversial and luxury issues in nuclear medicine

Affiliations

Superfluous, controversial and luxury issues in nuclear medicine

Authors

Affiliations

Similar articles

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources